CA
NZ
UK
AU
IND
US
…
Racura Oncology Ltd operates as a clinical-stage biopharmaceutical company in Australia. It develops RC220, a formulation of (E,E)-bisantrene, which is in Phase III clinical trial for the treatment of acute myeloid leukemia; Phase Ia/b clinical trial for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer; and Phase Ia/b clinical trial for the treatment of solid tumor cancers. The company was formerly known as Race Oncology Limited and changed its name to Racura Oncology Ltd in December 2025. Racura Oncology Ltd was incorporated in 2011 and is headquartered in Sydney, Australia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Race Oncology Ltd is an Australian clinical-stage biotechnology company focused on developing cancer therapies; publicly available disclosures are limited. Its long-term growth drivers may include clinical trial progress, regulatory approvals and licensing or partnership deals that could support development and commercialization, and investors may find potential upside from milestone-driven valuation inflection points tied to the company’s pipeline.
The primary investment risks are high clinical and regulatory risk, the likely need for additional financing with potential dilution, limited public information for assessment and strong competition in the oncology sector.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Income before tax | -13.87M | -4.79M | -17.82M | -9.92M | -11.20M |
| Net income | -11.09M | -4.79M | -13.82M | -9.92M | -11.20M |
| Selling general administrative | - | 0.74M | 0.91M | 1.44M | 3.78M |
| Selling and marketing expenses | - | 0.25M | 0.43M | 0.32M | 0.18M |
| Gross profit | -0.28M | 5.41M | 2.22M | 1.11M | -0.28M |
| Reconciled depreciation | - | 0.28M | 0.28M | 0.28M | 0.28M |
| Ebit | -12.43M | -4.72M | -14.48M | -13.65M | -11.96M |
| Ebitda | -12.15M | -4.43M | -14.20M | -13.37M | -11.68M |
| Depreciation and amortization | 0.28M | 0.28M | 0.28M | 0.28M | 0.28M |
| Operating income | -12.43M | -3.77M | -17.83M | -10.48M | -11.20M |
| Other operating expenses | 12.43M | 9.81M | 17.83M | -9.60M | -9.98M |
| Interest expense | - | - | - | - | 0.05M |
| Tax provision | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | - | 0.79M | 0.83M | 0.59M | 0.05M |
| Net interest income | - | 0.79M | 0.83M | 0.59M | 0.05M |
| Income tax expense | -2.78M | -5.25M | -4.00M | -0.59M | -0.05M |
| Total revenue | - | 6.04M | 4.00M | 3.13M | 0.71M |
| Total operating expenses | 12.15M | 9.18M | 17.55M | 13.65M | 11.96M |
| Cost of revenue | 0.28M | 0.64M | 0.28M | 2.03M | 0.99M |
| Total other income expense net | -1.44M | -1.02M | -4.44M | 3.13M | 0.71M |
| Net income from continuing ops | - | -4.79M | -13.82M | -9.92M | -11.20M |
| Net income applicable to common shares | - | -4.79M | -13.82M | -9.92M | -11.20M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Total assets | 38.09M | 17.49M | 20.23M | 26.64M | 37.52M |
| Intangible assets | 2.25M | 2.53M | - | 3.09M | 3.37M |
| Other current assets | 0.24M | - | 0.12M | - | 0.55M |
| Total liab | 1.64M | 1.48M | 1.92M | 1.15M | 1.42M |
| Total stockholder equity | 36.45M | 16.01M | 18.31M | 25.49M | 36.11M |
| Other current liab | 1.16M | - | 0.67M | 0.51M | 0.58M |
| Common stock | 101.00M | - | 66.95M | 61.71M | 62.02M |
| Capital stock | - | 68.49M | - | 61.71M | 62.02M |
| Retained earnings | -73.29M | -62.21M | -57.42M | -43.60M | -33.68M |
| Cash | 34.29M | 13.67M | 1.39M | 21.52M | 33.54M |
| Total current liabilities | 1.61M | 1.45M | 1.87M | 1.15M | 1.42M |
| Net debt | -34.29M | - | -1.39M | -21.52M | -33.54M |
| Short term debt | - | - | - | 0.00M | 0.00M |
| Other stockholder equity | - | - | - | -18.11M | -28.34M |
| Total current assets | 34.61M | 14.96M | 17.42M | 23.54M | 34.15M |
| Net tangible assets | - | - | - | 22.39M | 32.73M |
| Short term investments | - | - | 15.80M | - | - |
| Net receivables | 0.08M | - | 0.11M | 1.70M | 0.06M |
| Accounts payable | 0.46M | 0.46M | 1.20M | 0.64M | 0.83M |
| Accumulated other comprehensive income | 8.74M | - | 8.78M | 7.38M | 7.77M |
| Non currrent assets other | 1.23M | - | - | -3.09M | -3.37M |
| Non current assets total | 3.48M | 2.53M | 2.81M | 3.09M | 3.37M |
| Long term debt total | - | - | - | 0.00M | 0.00M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Investments | - | 0.00M | - | - | - |
| Change to liabilities | - | - | - | -0.27M | 0.89M |
| Total cashflows from investing activities | -0.00M | 0.00M | 0.00M | 0.00M | - |
| Total cash from financing activities | 28.87M | 1.06M | 5.21M | -1.28M | 30.51M |
| Change to operating activities | - | - | - | 0.23M | 0.59M |
| Net income | -11.09M | -4.79M | -13.82M | -9.92M | -11.20M |
| Change in cash | 20.62M | -3.52M | -4.33M | -12.02M | 24.22M |
| Begin period cash flow | 13.67M | 17.19M | 21.52M | 33.54M | 9.32M |
| End period cash flow | 34.29M | 13.67M | 17.19M | 21.52M | 33.54M |
| Total cash from operating activities | -8.25M | -4.57M | -9.55M | -10.65M | -6.26M |
| Issuance of capital stock | - | 1.06M | 5.21M | -1.28M | 30.98M |
| Depreciation | 0.28M | 0.28M | 0.28M | 0.28M | 0.28M |
| Other cashflows from investing activities | - | 0.00M | 0.00M | 0.00M | - |
| Change to account receivables | -0.05M | 0.08M | 1.60M | -1.64M | 0.07M |
| Sale purchase of stock | - | 1.06M | -0.00M | -1.28M | -0.46M |
| Other cashflows from financing activities | - | 0.00M | 5.21M | -1.28M | -0.00M |
| Change to netincome | - | - | - | 0.67M | 3.11M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | -0.09M | -1.04M | 1.88M | -1.64M | 0.07M |
| Stock based compensation | - | 1.42M | 1.43M | 0.59M | 3.07M |
| Other non cash items | 2.65M | -0.45M | 0.68M | -1.01M | 4.66M |
| Free cash flow | -8.25M | -4.57M | -9.55M | -10.65M | -6.26M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(AUD) |
Price
(AUD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| RAC Race Oncology Ltd |
-0.01 0.34% |
1.48 | - | - | 103.23 | 7.80 | -21.51 |
| CSL CSL Ltd |
-0.36 0.18% |
202.04 | - | 22.57 | 6.15 | 4.48 | 10.06 |
| TLX TELIX Pharmaceuticals Ltd |
-0.41 2.91% |
13.67 | 93.87 | 166.67 | 5.37 | 6.37 | 47.29 |
| NEU Neuren Pharmaceuticals Ltd |
- -% |
23.24 | 154.93 | 36.36 | 42.38 | 7.52 | 160.40 |
| MSB Mesoblast Ltd |
-0.14 6.45% |
2.03 | - | 454.55 | 23.43 | 3.36 | -9.86 |
Racura Oncology Ltd operates as a clinical-stage biopharmaceutical company in Australia. It develops RC220, a formulation of (E,E)-bisantrene, which is in Phase III clinical trial for the treatment of acute myeloid leukemia; Phase Ia/b clinical trial for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer; and Phase Ia/b clinical trial for the treatment of solid tumor cancers. The company was formerly known as Race Oncology Limited and changed its name to Racura Oncology Ltd in December 2025. Racura Oncology Ltd was incorporated in 2011 and is headquartered in Sydney, Australia.
| Name | Title | Year Born |
|---|---|---|
| Mr. Phillip R. Lynch | CEO, MD & Director | NA |
| Dr. Daniel Tillett | Chief Scientific Officer & Exec. Director | NA |
| Ms. Christina Manfre | Chief Financial Officer | NA |
| Dr. Ajay Duggal Dip Pharm Med, MB ChB, MRCP | Interim Chief Medical Officer | NA |
| Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D., MAICD | Company Sec. | 1963 |
| Dr. Daniel Tillett | Chief Executive Officer | NA |
| Dr. Peter M. Smith Ph.D. | Executive Director | 1963 |
| Prof. Tim Hammond | Interim Chief Scientific Officer | NA |
| Dr. Michelle Rashford | Chief Medical Officer | NA |
| Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D. | Company Secretary | 1963 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.61%
Communication Services
-0.21%
Consumer Cyclical
-0.26%
Consumer Defensive
-0.37%
Energy
+0.23%
Financial Services
-0.43%
Financials
+0.39%
Healthcare
+0.88%
Industrials
+0.36%
Real Estate
-0.51%
Technology
+1.35%
Utilities
+0.19%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...